ArticleThe Neurohospitalist2026
Fulminant Amyloid-β-Related Angiitis after Tenecteplase: A Biopsy-Confirmed Cause of Post-Thrombolysis Neurologic Deterioration.
Article in The Neurohospitalist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amyloid-β-related angiitis (ABRA) is a rare steroid-responsive inflammatory vasculopathy that can mimic or complicate acute cerebrovascular disease. Its interaction with thrombolytic therapy is poorly understood. We report a biopsy-confirmed case of fulminant ABRA temporally associated with intravenous tenecteplase. Case Description: An 86-year-old man presented with acute painless monocular vision loss and received tenecteplase for presumed central retinal artery occlusion. Initial imaging showed no hemorrhage. Within 24 hours, he developed progressive encephalopathy with a large left frontal lobar hemorrhage, additional contralateral lobar hemorrhages, and diffuse subarachnoid hemorrhage requiring surgical evacuation. Pathology demonstrated Congo red-positive amyloid deposition with transmural lymphocytic and macrophage-predominant inflammation and fibrinoid necrosis, confirming ABRA. MRI showed progressive vasogenic edema, new punctate infarcts, increasing cortical microbleeds, and convexity subarachnoid hemorrhage. Infectious evaluation was negative. High-dose corticosteroids led to gradual neurologic improvement. Conclusions: Thrombolysis may unmask or exacerbate inflammatory cerebral amyloid angiopathy, causing multifocal hemorrhage, ischemia, and rapid decline. In older patients with unexpected post-thrombolysis deterioration and evolving lobar hemorrhage, edema, and microbleeds, ABRA should be considered, as early immunosuppression may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.